Feed excerpt — reported by The Hill
The White House's abrupt withdrawal of Heidi Overton as President Trump's nominee to lead the Food and Drug Administration (FDA) means the agency will remain without stable leadership six months after the former commissioner resigned, leaving industry observers anxious. The Trump administration's last-minute pulling of Overton's nomination caught senators by surprise this week. Sen. Bill Cassidy (R-La.), chair of the Senate Health,…
MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at The Hill →